CU24017B1 - Compuestos etanamínicos para tratar la depresión - Google Patents
Compuestos etanamínicos para tratar la depresiónInfo
- Publication number
- CU24017B1 CU24017B1 CU2011000141A CU20110141A CU24017B1 CU 24017 B1 CU24017 B1 CU 24017B1 CU 2011000141 A CU2011000141 A CU 2011000141A CU 20110141 A CU20110141 A CU 20110141A CU 24017 B1 CU24017 B1 CU 24017B1
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- pharmaceutically acceptable
- ethanaminal
- acceptable salt
- treat depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
Abstract
La presente invención trata de compuestos 2-metil-1-fenil-2-(piridin-2-il)propan-1-amina o una sal farmaceuticamente aceptable del mismo y su isómero (S)-2-metil-1-fenil-2-(piridin-2-il)propan-1-amina o una sal farmaceuticamente aceptable del mismo donde la sal farmaceuticamente aceptable es una sal formada a partir de sulfúrico, fosfórico, cítrico, tartárico, láctico, pirúvico, acético, succínico, fumárico, ácido clorhídrico, bromhídrico, maleico, metanosulfónico, o bencenosulfónico. Estos compuestos son útiles para el tratamiento de la depresión.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14067308P | 2008-12-24 | 2008-12-24 | |
PCT/SE2009/051493 WO2010074647A1 (en) | 2008-12-24 | 2009-12-22 | Ethanamine compounds and their use for treating depression |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20110141A7 CU20110141A7 (es) | 2012-01-31 |
CU24017B1 true CU24017B1 (es) | 2014-07-30 |
Family
ID=42288011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2011000141A CU24017B1 (es) | 2008-12-24 | 2011-06-24 | Compuestos etanamínicos para tratar la depresión |
Country Status (31)
Country | Link |
---|---|
US (4) | US8013165B2 (es) |
EP (2) | EP2610246A1 (es) |
JP (1) | JP5491524B2 (es) |
KR (1) | KR20110097996A (es) |
CN (1) | CN102333762B (es) |
AR (1) | AR074981A1 (es) |
AU (1) | AU2009330745B2 (es) |
BR (1) | BRPI0923476A2 (es) |
CA (1) | CA2748235A1 (es) |
CL (1) | CL2011001590A1 (es) |
CO (1) | CO6450688A2 (es) |
CR (1) | CR20110365A (es) |
CU (1) | CU24017B1 (es) |
DO (1) | DOP2011000205A (es) |
EA (1) | EA201190064A1 (es) |
EC (1) | ECSP11011161A (es) |
GT (1) | GT201100186A (es) |
HN (1) | HN2011001773A (es) |
IL (1) | IL213518A0 (es) |
MX (1) | MX2011006680A (es) |
NI (1) | NI201100131A (es) |
NZ (1) | NZ593282A (es) |
PE (1) | PE20120249A1 (es) |
SA (1) | SA109310013B1 (es) |
SG (2) | SG192510A1 (es) |
SV (1) | SV2011003962A (es) |
TW (1) | TWI442922B (es) |
UA (1) | UA106056C2 (es) |
UY (1) | UY32360A (es) |
WO (1) | WO2010074647A1 (es) |
ZA (1) | ZA201105441B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG192510A1 (en) | 2008-12-24 | 2013-08-30 | Astrazeneca Ab | Ethanamine compounds and their use for treating depression |
CN112279843B (zh) * | 2020-11-24 | 2023-05-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种具有抗抑郁活性的含氮杂环化合物 |
CN112250676B (zh) * | 2020-11-24 | 2023-05-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种具有抗抑郁活性的含氧杂环化合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3422191A (en) | 1965-01-21 | 1969-01-14 | Synergistics Inc | Compositions and methods for tranquilization employing salts of n-morpholine ethanol |
GB1427026A (en) | 1972-11-20 | 1976-03-03 | Ici Ltd | Synthetic film materials |
JPS5756474B2 (es) | 1973-05-26 | 1982-11-30 | ||
US5455259A (en) | 1987-02-06 | 1995-10-03 | Fisons Corporation | Compounds for the treatment of neurodegenerative disorders |
GB9320273D0 (en) | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
EP0356035B1 (en) | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
JP2514855B2 (ja) | 1990-08-08 | 1996-07-10 | キッセイ薬品工業株式会社 | 光学活性なアラニンアニリド誘導体の酸付加塩 |
US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
US5607935A (en) | 1991-10-30 | 1997-03-04 | Fisons Corporation | 2-heterocyclicethylamine derivatives and their use as pharmaceuticals |
NZ251384A (en) | 1992-04-03 | 1996-10-28 | Fisons Corp | (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments |
EP0898566B1 (en) * | 1996-04-19 | 2002-11-06 | Akzo Nobel N.V. | Substituted benzylamines and their use for the treatment of depression |
DE69809827D1 (de) | 1997-03-31 | 2003-01-16 | Korea Res Inst Chem Tech | Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung |
TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
SG192510A1 (en) | 2008-12-24 | 2013-08-30 | Astrazeneca Ab | Ethanamine compounds and their use for treating depression |
-
2009
- 2009-12-22 SG SG2013053749A patent/SG192510A1/en unknown
- 2009-12-22 EA EA201190064A patent/EA201190064A1/ru unknown
- 2009-12-22 AU AU2009330745A patent/AU2009330745B2/en not_active Ceased
- 2009-12-22 EP EP13159532.4A patent/EP2610246A1/en not_active Withdrawn
- 2009-12-22 CA CA2748235A patent/CA2748235A1/en not_active Abandoned
- 2009-12-22 SG SG2011040342A patent/SG171928A1/en unknown
- 2009-12-22 UA UAA201107171A patent/UA106056C2/uk unknown
- 2009-12-22 MX MX2011006680A patent/MX2011006680A/es active IP Right Grant
- 2009-12-22 NZ NZ593282A patent/NZ593282A/xx not_active IP Right Cessation
- 2009-12-22 KR KR1020117017236A patent/KR20110097996A/ko not_active Application Discontinuation
- 2009-12-22 US US12/644,046 patent/US8013165B2/en not_active Expired - Fee Related
- 2009-12-22 BR BRPI0923476A patent/BRPI0923476A2/pt not_active IP Right Cessation
- 2009-12-22 WO PCT/SE2009/051493 patent/WO2010074647A1/en active Application Filing
- 2009-12-22 SA SA109310013A patent/SA109310013B1/ar unknown
- 2009-12-22 PE PE2011001282A patent/PE20120249A1/es not_active Application Discontinuation
- 2009-12-22 CN CN200980157411.9A patent/CN102333762B/zh not_active Expired - Fee Related
- 2009-12-22 JP JP2011543474A patent/JP5491524B2/ja not_active Expired - Fee Related
- 2009-12-22 EP EP09835355A patent/EP2391606A4/en not_active Withdrawn
- 2009-12-23 UY UY0001032360A patent/UY32360A/es not_active Application Discontinuation
- 2009-12-23 TW TW098144591A patent/TWI442922B/zh not_active IP Right Cessation
- 2009-12-23 AR ARP090105104A patent/AR074981A1/es not_active Application Discontinuation
-
2011
- 2011-06-13 IL IL213518A patent/IL213518A0/en unknown
- 2011-06-24 EC EC2011011161A patent/ECSP11011161A/es unknown
- 2011-06-24 CU CU2011000141A patent/CU24017B1/es not_active IP Right Cessation
- 2011-06-24 SV SV2011003962A patent/SV2011003962A/es unknown
- 2011-06-24 CL CL2011001590A patent/CL2011001590A1/es unknown
- 2011-06-24 HN HN2011001773A patent/HN2011001773A/es unknown
- 2011-06-24 NI NI201100131A patent/NI201100131A/es unknown
- 2011-06-24 CR CR20110365A patent/CR20110365A/es unknown
- 2011-06-24 DO DO2011000205A patent/DOP2011000205A/es unknown
- 2011-06-24 GT GT201100186A patent/GT201100186A/es unknown
- 2011-06-29 CO CO11081454A patent/CO6450688A2/es not_active Application Discontinuation
- 2011-07-22 ZA ZA2011/05441A patent/ZA201105441B/en unknown
- 2011-08-29 US US13/219,892 patent/US20120115913A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,303 patent/US20120277272A1/en not_active Abandoned
-
2013
- 2013-01-24 US US13/748,852 patent/US9035065B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2020032I1 (el) | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια | |
MX2012002758A (es) | Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas. | |
EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
TW201129555A (en) | Process for the manufacture of dabigatrane etexilate | |
MX2012002761A (es) | Bipiridinas utiles para el tratamiento de enfermedades proliferativas. | |
ECSP11011157A (es) | Inhibidores de proteína cinasa | |
WO2011027249A3 (en) | Benzimidazole derivatives | |
CO6362012A2 (es) | Clohidarto de nalmefeno dihidratado | |
EA201100613A1 (ru) | Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций | |
EP2440251A4 (en) | INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION | |
EA201100299A1 (ru) | Органические соединения | |
EA201270616A1 (ru) | Ингибиторы вируса гепатита с | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
EA201270492A1 (ru) | Соединения для лечения дислипидемии и связанных с ней заболеваний | |
NO20092464L (no) | Faste former av rasemisk ilaprazol | |
CY1116043T1 (el) | Κρυσταλλικες μορφες υδροχλωρικου αλατος (4α-r,9α-s)-1-(1η-βενζοϊμιδαζολο-5-καρβονυλ)2,3,4,4α,9,9α-εξαϋδρο-1η-ινδενο[2,1-β]πυριδινο-6-καρβονιτριλιου και χρηση τους ως αναστολεις της hsd 1 | |
EA201001524A1 (ru) | Ингибиторы дезацетилазы в, основанные на гидроксамате | |
EA201171273A1 (ru) | Средство для профилактики и лечения высокопатогенных инфекционных заболеваний | |
WO2013014665A8 (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
ITTO20110634A1 (it) | Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia | |
CU24017B1 (es) | Compuestos etanamínicos para tratar la depresión | |
MA32183B1 (fr) | Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt | |
WO2013111163A3 (en) | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof | |
WO2010123545A3 (en) | Angiogenesis inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse (for not paying fees) |